Dieckmann, A <br/><br/>
Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation.  [electronic resource] 

 -  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association  Mar 2012 
 - 132-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1439-3646 
<br/><br/><label>Standard No.: </label>10.1055/s-0031-1291248  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Central Nervous System Stimulants--pharmacology<br/>Diabetes Mellitus, Experimental--chemically induced<br/>Diabetic Neuropathies--pathology<br/>Drug Evaluation, Preclinical<br/>Enzyme Inhibitors--pharmacology<br/>Heme--analogs & derivatives<br/>Male<br/>Poly Adenosine Diphosphate Ribose--antagonists & inhibitors<br/>Poly(ADP-ribose) Polymerase Inhibitors<br/>Rats<br/>Rats, Sprague-Dawley<br/>Sensory Receptor Cells--drug effects<br/>Signal Transduction--drug effects<br/>Streptozocin